🇺🇸 Mitozantrone in United States

15 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Myelodysplastic Syndrome — 3 reports (20%)
  2. Neutropenia — 2 reports (13.33%)
  3. Neutropenic Sepsis — 2 reports (13.33%)
  4. Pancytopenia — 2 reports (13.33%)
  5. Acute Leukaemia — 1 report (6.67%)
  6. Ascites — 1 report (6.67%)
  7. Ataxia — 1 report (6.67%)
  8. Atrial Fibrillation — 1 report (6.67%)
  9. B-Cell Lymphoma — 1 report (6.67%)
  10. Bone Marrow Failure — 1 report (6.67%)

Source database →

Other Oncology approved in United States

Frequently asked questions

Is Mitozantrone approved in United States?

Mitozantrone does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Mitozantrone in United States?

US Department of Veterans Affairs is the originator. The local marketing authorisation holder may differ — check the official source linked above.